Shares in Penumbra (NYSE:PEN) rose today after the medical device maker topped expectations on Wall Street with its first quarter 2018 earnings results. The Alameda, Calif.-based company posted profits of $5.5 million, or 15¢ per share, on sales of $102.7 million for the three months ended March 31, seeing a swing from the red on the […]
Penumbra shares rise on Q4, FY2017 earnings beat
Shares in Penumbra (NYSE:PEN) rose today after the medical device maker met expectations on Wall Street with its fourth quarter and fiscal year 2017 earnings results. The Alameda, Calif.-based company posted profits of $9.1 million, or 25¢ per share, on sales of $96 million for the 3 months ended December 31, seeing a massive swing from […]
Penumbra touts non-inferiority in Compass aspiration thrombectomy trial
Penumbra (NYSE:PEN) late last month released results from the Compass trial of its aspiration thrombectomy system designed to treat acute ischemic stroke, touting that the system was shown to be non-inferior to stent retrievers. Results from the trial were presented at the International Stroke Conference, the Alameda, Calif.-based company said. Investigators in the trial aimed to […]
Penumbra touts real-world study results in Penumbra System acute ischemic stroke trial
Penumbra (NYSE:PEN) today released results from the Promise real-world safety and efficacy study of its Penumbra System with ACE 68 and 64 reperfusion catheters as a treatment for patients with acute ischemic stroke, touting high rates of revascularization and low rates of all-cause mortality. Results were presented at the International Stroke Conference this week in Los Angeles. […]
Penumbra, Sixense launch VR JV MVI Health
Penumbra (NYSE:PEN) said today it inked a deal with Sixense Enterprises to launch the new virtual reality healthcare joint venture MVI Health. The new JV will be headquartered in Alameda, Cali., and will be headed by Penumbra CEO Adam Elsesser. Penumbra will support the company with investments while Sixense will suport it through licensing, intellectual property and […]
Penumbra’s Q3 results top estimates
Penumbra (NYSE:PEN) yesterday reported third-quarter results that topped the consensus forecast on Wall Street and raised its sales outlook for the rest of the year, despite a nearly 100% profit slide. The Alameda, Calif.-based medical device company posted profits of $238,000, or 1¢ per share, on sales of $83.9 million for the three months ended […]
FDA recalls Penumbra 3D Revascularization device over wire separation issues
The FDA today released a recall notice for Penumbra‘s (NYSE:PEN) 3D Revascularization Device, part of its Penumbra system designed to remove thrombus from brain blood vessels during strokes, over issues with wire breaks and separations. The FDA labeled the recall as Class I, its most serious designation, indicating that there is a reasonable probability that use […]
Penumbra picks up Italian distributor Crossmed for $9m
Penumbra (NYSE:PEN) said today it paid $9.4 million (EU €8.2 million) for all outstanding shares of Italian Crossmed S.p.a., which operated as the company’s exclusive distributor in Italy, San Marino and the Vatican. Alameda, Calif.-based Penumbra said that with the acquisition, Crossmed is now a wholly-owned subsidiary of the company. Penumbra added that there are no […]
Penumbra prices $99m offering
Penumbra (NYSE:PEN) said today that it priced a public offering worth nearly $99 million, not including an underwriter’s option worth nearly $15 million. Alameda, Calif.-based Penumbra makes a line of instruments designed for neurovascular and peripheral vascular procedures, including stroke revascularization, embolization and thrombectomy. The company said it plans to float 1.3 million shares at $76 […]
Penumbra shares rise on whopping Q4, FY2016 earnings beat
Shares in Penumbra (NYSE:PEN) have soared today after the medical device maker topped expectations on Wall Street with its 4th quarter and fiscal year 2016 earnings results. The Alameda, Calif.-based company posted losses of $2.4 million, or 8¢ per share, on sales of $73.1 million for the 3 months ended Dec. 31, with the bottom-line […]
Penumbra: Stroke study shows aspiration system equal to stent retrievers
Penumbra (NYSE:PEN) touted data from the Aster trial evaluating its aspiration system compared to a stent retriever as a first-line thrombectomy approach for acute ischemic stroke. The data showed that the company’s direct aspiration, first-pass technique (Adapt) compared favorably with a stent retriever – 85.4% of patients treated with Penumbra’s aspiration system met the study’s […]
MassDevice Network
@MassDevice
LinkedIn
Google+